Australia Biosimulation Market (2026-2031)
The Australia Biosimulation Market was valued at $43.1 Million in 2026 and projected to reach to $90.8 Million by 2031, representing a compound annual growth rate of 16.1%. Australia's biosimulation market is positioned for significant expansion as pharmaceutical and biotech companies recognize the technology's potential to streamline drug development processes.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia Biosimulation Market Trends and Insights
- Australia is increasingly adopting biosimulation technologies to accelerate drug development, reduce clinical trial costs, and improve regulatory approval timelines.
- The market in Australia benefits from strong pharmaceutical R&D infrastructure, government support for healthcare innovation, and growing collaboration between academic institutions and industry players. The 16.1% compound annual growth rate reflects Australia's commitment to precision medicine and computational biology.
- Australia's biosimulation adoption is driven by rising demand for personalized therapeutics, integration of artificial intelligence in drug discovery, and regulatory incentives for innovative development approaches.
- By 2031, Australia is expected to solidify its position as a key biosimulation hub within the Asia Pacific region, supported by increasing investment in digital health technologies and biopharmaceutical research capabilities..
Key Market Statistics
- CAGR (2026-2031) 16.1% CAGR
- Market Size, 2026 ~USD 43.1 Million
- Forecast, 2031 ~USD 90.8 Million
- Country Australia
Australia Biosimulation Market Overview
Market Valuation Growth :
Australia's biosimulation market is valued at $43.1 million in 2026 and is projected to reach $90.8 million by 2031, representing a robust 16.1% CAGR over the forecast period.
Strong R&D Infrastructure :
Australia benefits from a well-established pharmaceutical research and development ecosystem, with leading institutions and biotech companies driving innovation in computational drug modeling and simulation technologies.
Clinical Trial Optimization :
Australian pharmaceutical companies are increasingly leveraging biosimulation to reduce clinical trial costs, accelerate drug development timelines, and improve regulatory approval processes with the TGA.
Government Support & Regulation :
Australia's regulatory framework and government initiatives supporting life sciences innovation create a favorable environment for biosimulation adoption across the healthcare and pharmaceutical sectors.
Australia Biosimulation Market Dynamics
- The adoption of in silico modeling and simulation tools is accelerating, driven by the need to reduce costs and timelines associated with traditional clinical trials.
- Government backing and investment in life sciences infrastructure further strengthen market conditions.
- By 2031, the market is expected to nearly double, reflecting increased integration of biosimulation into regulatory submissions and preclinical development strategies across Australian pharmaceutical organizations..
Related Ecosystem
Healthcare It
Key Takeaways
- Australia's biosimulation market will nearly double from $43.1M (2026) to $90.8M (2031), representing a 16.1% CAGR.
- Australia is leveraging biosimulation to reduce drug development timelines and clinical trial costs in the biopharmaceutical sector.
- Government support and academic-industry partnerships are accelerating biosimulation adoption across Australia's healthcare ecosystem.
- Australia's biosimulation market growth is fueled by AI integration, precision medicine demand, and regulatory innovation incentives.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | DATA ANALYSIS & INTERPRETATION (Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | SOFTWARE (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Offering, Type, Phase Of Development |
Australia Biosimulation Market Report Segmentation
3 segment dimensions are covered across the global market.
By Offering
- Services
- Software
By Type
- Consulting & Advisory
- Data Analysis & Interpretation
- Implementation, Training, And Support
By Phase Of Development
- Commercial & Market Access
- Drug Discovery
- Early Clinical Development
- Late Clinical Development
- Preclinical Development
- Regulatory
AUSTRALIA: BIOSIMULATION MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 4.13 | 4.73 | 5.42 | 6.22 | 7.15 | 8.25 | 9.52 | 11.02 | 15.2 |
| CONTRACT RESEARCH ORGANIZATIONS | 7.95 | 9.25 | 10.78 | 12.59 | 14.72 | 17.26 | 20.28 | 23.89 | 17.3 |
| OTHER END USERS | 2.76 | 3.08 | 3.44 | 3.84 | 4.28 | 4.77 | 5.3 | 5.86 | 11.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 23.8 | 27.83 | 32.6 | 38.26 | 44.97 | 53.01 | 62.58 | 74.02 | 17.8 |
| REGULATORY BODIES | 1.91 | 2.19 | 2.53 | 2.92 | 3.38 | 3.92 | 4.55 | 5.3 | 15.9 |
| TOTAL | 40.54 | 47.08 | 54.77 | 63.83 | 74.51 | 87.2 | 102.24 | 120.09 | 17 |
Target Audience
- Pharmaceutical Companies : Australian and international pharma firms need market intelligence to optimize R&D investments, accelerate drug development timelines, and improve regulatory approval success rates through biosimulation adoption.
- Biotech & CRO Organizations : Contract research organizations and biotech companies require detailed market data to identify service expansion opportunities, competitive positioning, and client demand for biosimulation-enabled drug development services.
- Software & Technology Vendors : Biosimulation software providers and technology companies need Australia-specific market insights to tailor solutions, identify customer segments, and develop go-to-market strategies for the region.
- Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Australia's life sciences sector require comprehensive market data to assess growth potential, identify acquisition targets, and make informed funding decisions.
- Government & Regulatory Bodies : Australian health authorities and policy makers need market analysis to understand biosimulation's impact on drug development efficiency, regulatory timelines, and healthcare innovation policy development.
Key Companies in the Australia Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Reasons to Buy this Report
- Market Size & Growth Trajectory : Gain precise valuation data for Australia's biosimulation market with detailed forecasts through 2031, enabling accurate investment planning and resource allocation decisions for market entry or expansion.
- Competitive Landscape Intelligence : Understand the competitive dynamics specific to Australia's biosimulation sector, including key players, market share distribution, and strategic positioning to identify partnership and acquisition opportunities.
- Regulatory & Government Insights : Access detailed analysis of Australia's regulatory environment, TGA requirements, and government support mechanisms that influence biosimulation adoption and market growth trajectories.
- Sector-Specific Adoption Trends : Identify which Australian pharmaceutical, biotech, and CRO segments are leading biosimulation adoption, including use cases in drug development, clinical trial design, and regulatory submissions.
- Strategic Market Positioning : Develop data-driven strategies for market penetration in Australia by understanding local demand drivers, customer pain points, and growth opportunities within the region's healthcare ecosystem.
Frequently asked questions
What is the current size of Australia's biosimulation market?
Australia's biosimulation market is valued at $43.1 million in 2026 and is expected to grow to $90.8 million by 2031.
What is the growth rate of biosimulation in Australia?
Australia's biosimulation market is growing at a compound annual growth rate (CAGR) of 16.1% from 2026 to 2031.
What are the main drivers of biosimulation adoption in Australia?
Key drivers include rising demand for personalized therapeutics, AI integration in drug discovery, regulatory incentives for innovation, and strong pharmaceutical R&D infrastructure in Australia.
How does Australia's biosimulation market compare to the Asia Pacific region?
Australia is emerging as a significant biosimulation hub within Asia Pacific, supported by government backing, academic excellence, and biopharmaceutical investment that positions Australia competitively in the regional market.
What applications of biosimulation are most prevalent in Australia?
Australia's biosimulation applications focus on drug development acceleration, clinical trial optimization, personalized medicine development, and regulatory pathway streamlining for biopharmaceutical companies.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
- Brazil Biosimulation Market
- Mexico Biosimulation Market
- Saudi Arabia Biosimulation Market
- UAE Biosimulation Market
- South Africa Biosimulation Market
- US Biosimulation Market
- Canada Biosimulation Market
- Germany Biosimulation Market
- France Biosimulation Market
- UK Biosimulation Market
- Italy Biosimulation Market
- Spain Biosimulation Market
- China Biosimulation Market
- Japan Biosimulation Market
- India Biosimulation Market
- South Korea Biosimulation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
